Jane Street Group LLC Invests $39,000 in Immix Biopharma, Inc. (NASDAQ:IMMX)

Posted by Defense World Staff on Jun 10th, 2025

Jane Street Group LLC acquired a new position in shares of Immix Biopharma, Inc. (NASDAQ:IMMX – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 17,523 shares of the company’s stock, valued at approximately $39,000. Jane Street Group LLC owned approximately 0.06% of Immix Biopharma at the end of the most recent quarter.

Separately, SBI Securities Co. Ltd. bought a new position in shares of Immix Biopharma during the 4th quarter worth approximately $38,000. Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Price Performance

Immix Biopharma stock opened at $2.34 on Tuesday. The company has a market capitalization of $65.23 million, a PE ratio of -2.75 and a beta of 0.31. Immix Biopharma, Inc. has a one year low of $1.26 and a one year high of $3.00. The business has a 50 day simple moving average of $1.92 and a 200 day simple moving average of $1.95.

Immix Biopharma (NASDAQ:IMMX – Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.09. Equities analysts anticipate that Immix Biopharma, Inc. will post -0.87 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Immix Biopharma in a research report on Wednesday, June 4th.

Check Out Our Latest Research Report on IMMX

Immix Biopharma Company Profile

(Free Report)

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.